These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20980172)

  • 21. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin.
    Su Z; Izumi T; Thames EH; Lawson JH; Ortel TL
    J Lab Clin Med; 2002 Jun; 139(6):349-56. PubMed ID: 12066133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.
    Ortel TL; Mercer MC; Thames EH; Moore KD; Lawson JH
    Ann Surg; 2001 Jan; 233(1):88-96. PubMed ID: 11141230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
    Savage WJ; Kickler TS; Takemoto CM
    Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy.
    Pavlovich CP; Battiwalla M; Rick ME; Walther MM
    J Urol; 2001 May; 165(5):1617. PubMed ID: 11342931
    [No Abstract]   [Full Text] [Related]  

  • 25. Preclinical safety of recombinant human thrombin.
    Heffernan JK; Ponce RA; Zuckerman LA; Volpone JP; Visich J; Giste EE; Jenkins N; Boster D; Pederson S; Knitter G; Palmer T; Wills M; Early RJ; Rogge MC
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):48-58. PubMed ID: 16971028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exposure of mice to topical bovine thrombin induces systemic autoimmunity.
    Schoenecker JG; Johnson RK; Lesher AP; Day JD; Love SD; Hoffman MR; Ortel TL; Parker W; Lawson JH
    Am J Pathol; 2001 Nov; 159(5):1957-69. PubMed ID: 11696457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis.
    Chapman WC; Singla N; Genyk Y; McNeil JW; Renkens KL; Reynolds TC; Murphy A; Weaver FA
    J Am Coll Surg; 2007 Aug; 205(2):256-65. PubMed ID: 17660072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical bovine thrombin and adverse events: a review of the literature.
    Clark J; Crean S; Reynolds MW
    Curr Med Res Opin; 2008 Jul; 24(7):2071-87. PubMed ID: 18549663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis.
    Paterson CA; Pixton GC; Proskin HM; Massaro JM; Morasch M; Cronstein B; Fareed J; Ofosu FA
    Clin Appl Thromb Hemost; 2011; 17(6):620-32. PubMed ID: 21596694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieving hemostasis in the surgical field.
    Boucher BA; Traub O
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):2S-7S. PubMed ID: 19558278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
    Lo CY; Jones C; Glader B; Zehnder JL
    Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting.
    Greenhalgh DG; Gamelli RL; Collins J; Sood R; Mozingo DW; Gray TE; Alexander WA
    J Burn Care Res; 2009; 30(3):371-9. PubMed ID: 19349898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical use of recombinant human thrombin for operative hemostasis.
    Anderson CD; Bowman LJ; Chapman WC
    Expert Opin Biol Ther; 2009 Jan; 9(1):133-7. PubMed ID: 19063699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical use and immunologic impact of thrombin in surgery.
    Lawson JH
    Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():98-110. PubMed ID: 16673271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The use of modern hemostatics in surgery of long bones' ostheomyelitis and prosthetic infections of coxofemoral and knee joints].
    Riabov AL; Kulabukhov VV; Ivanov AK
    Khirurgiia (Mosk); 2011; (9):76-7. PubMed ID: 22413166
    [No Abstract]   [Full Text] [Related]  

  • 36. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma.
    Nelson PA; Powers JN; Estridge TD; Elder EA; Alea AD; Sidhu PK; Sehl LC; DeLustro FA
    J Biomed Mater Res; 2001; 58(6):710-9. PubMed ID: 11745525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
    Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
    Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative purity of thrombin-based hemostatic agents used in surgery.
    Schoenecker JG; Johnson RK; Fields RC; Lesher AP; Domzalski T; Baig K; Lawson JH; Parker W
    J Am Coll Surg; 2003 Oct; 197(4):580-90. PubMed ID: 14522327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery.
    Doria C; Fischer CP; Wood CG; Li PM; Marra S; Hart J
    Curr Med Res Opin; 2008 Mar; 24(3):785-94. PubMed ID: 18241525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
    Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
    J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.